Neurofeedback treatment for PTSD
Neurofeedback for Post-Traumatic Stress Disorder (N-PTSD). A Randomized Trial of Neurofeedback.
This study is testing if adding neurofeedback therapy to standard treatment can help people with tough-to-treat PTSD feel better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sahlgrenska University Hospital Academic / other |
| Locations | 1 site (Gothenburg, Västra Götaland) |
| Trial ID | NCT05123690 on ClinicalTrials.gov |
What this trial studies
This pilot study investigates the effectiveness of neurofeedback combined with standard treatment for patients with treatment-resistant Post-Traumatic Stress Disorder (PTSD). Thirty participants will be randomly assigned to either receive neurofeedback therapy alongside their usual treatment or be placed on a waiting list for treatment. The neurofeedback sessions will occur twice a week over a 12-week period, with assessments conducted before and after the treatment. The aim is to evaluate the potential benefits of neurofeedback in improving PTSD symptoms.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a diagnosis of treatment-resistant PTSD who have undergone prior psychotherapy or pharmacological treatment.
Not a fit: Patients with ongoing traumatic exposure, severe mental health issues, or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a novel therapeutic option for patients with treatment-resistant PTSD.
How similar studies have performed: While neurofeedback has been explored in various contexts, this specific approach for treatment-resistant PTSD is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * CAPS Cutoff \>44 * Stable psychopharmacological treatment (stable dose, no planned changes during the course of the trial) * AUDIT cut off \<16 * DUDIT cut off \<8 * Already undergone at least one treatment with psychotherapy and/or pharmacological treatment for a minimum of 6 months. * 18 years or older Exclusion Criteria: * Diagnosis of traumatic brain injury (TBI) affecting capability to give informed consent * Ongoing traumatic exposure (such as domestic violence) * Balance problems * Active suicide risk or life-threatening self-harm * A diagnosis of schizophrenia or psychotic disorder * Ongoing compulsory care * If the patient changes dose or medication strategy during the trial. * If the neurofeedback treatment is identified as a primary reason for worsening of participant's well being.
Where this trial is running
Gothenburg, Västra Götaland
- Sahlgrenska University Hospital — Gothenburg, Västra Götaland, Sweden (Recruiting)
Study contacts
- Principal investigator: Steinn Steingrimsson, PhD — Sahlgrenska University Hospital
- Study coordinator: Steinn Steingrimsson, PhD
- Email: steinn.steingrimsson@vgregion.se
- Phone: 0046313421000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.